Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Nuvilex, Inc. (NVLX)

Add NVLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Alydyr, Pennystockplayer, thnikkamax, Peacefulwendy, TheBestInvest, PetePham
Search This Board:
Last Post: 10/21/2014 9:02:38 PM - Followers: 491 - Board type: Free - Posts Today: 33


ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


Nuvilex Company Address
   Nuvilex, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Shares Outstanding:
709,256,214 a/o Aug 26, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data
Short Interest: 8,450,144 a/o Aug 29, 2014

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Clare Matschullat 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 106 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide.

Nuvilex has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed.



Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.


Medical Marijuana Sciences





Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVLX News: Nuvilex Contracts with University of Veterinary Medicine in Vienna to Conduct Preclinical Studies to Develop Diabetes Treatment 10/20/2014 09:00:00 AM
NVLX News: Securities Registration Statement (simplified Form) (s-3) 10/17/2014 04:00:54 PM
NVLX News: Amended Annual Report (10-k/a) 10/17/2014 05:59:23 AM
NVLX News: Amended Annual Report (10-k/a) 10/17/2014 05:59:23 AM
NVLX News: Nuvilex Secures Worldwide License for Insulin-Producing Cells for Use in Developing Diabetes Treatment 10/16/2014 09:00:00 AM
#27216  Sticky Note PR OUT...Nuvilex Contracts With University of Veterinary Medicine bulldurham 10/20/14 09:04:54 AM
#27185  Sticky Note Nuvilex Applies to FDA for Orphan Drug Designation PetePham 10/17/14 09:58:02 PM
#27095  Sticky Note The SEC has contacted NVLX - Not good Alydyr 10/17/14 09:59:44 AM
#24584  Sticky Note What is Cell-in-the-Box? PetePham 07/28/14 04:14:36 PM
#20481  Sticky Note Normally I might be inclined to agree with Going Coastal 05/02/14 03:16:58 PM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#27271   If I can manipulate nvlx's stock single handedly LuCo 10/21/14 09:31:34 PM
#27269   This Definition Might Help: Setay 10/21/14 09:01:34 PM
#27268   I wouldn't say I was bashing at all. LuCo 10/21/14 08:45:49 PM
#27266   Nuvilex's future with the FDA is golden with joe_techi 10/21/14 07:45:32 PM
#27265   I wouldn't say I was bashing at all. LuCo 10/21/14 07:44:00 PM
#27264   For this very reason I believe Nuvilex wanted young_wolf_350 10/21/14 07:00:23 PM
#27263   So LuCo you're no longer bashing the company? According PiieTwo 10/21/14 06:53:55 PM
#27262   I purchased more today @ $0.236. If it pennyvestor 10/21/14 04:31:53 PM
#27261   5,000 More! Pure Gold... Setay 10/21/14 03:47:38 PM
#27260   The outstanding share count is my only "beef" pjbwheeeze 10/21/14 02:16:02 PM
#27259   Thanks tombrady12nh 10/21/14 02:11:50 PM
#27258   Outstanding shares and float count can be found Peacefulwendy 10/21/14 01:58:43 PM
#27257   Can someone tell me the Outstanding Share count tombrady12nh 10/21/14 12:52:42 PM
#27255   Hire the writer for us young_wolf_350 10/21/14 12:42:20 PM
#27254   My 1 post per day.... The Promised Land 10/21/14 12:41:55 PM
#27253   What will a Nice Forbes Follow-Up Article and Setay 10/21/14 12:41:34 PM
#27252   Forbes: Setay 10/21/14 12:40:17 PM
#27251   And this Forbe's Early 2013 Article was before Setay 10/21/14 12:38:05 PM
#27250   Good point. Otsy 10/21/14 12:14:59 PM
#27249   The last report that SMMG put out was Emmmci 10/21/14 11:15:50 AM
#27248   Nuvilex is very good at what they do...putting bulldurham 10/21/14 11:03:12 AM
#27247   every time smmg put out a report the thenewmixer 10/21/14 10:36:06 AM
#27246   This may answer your questions. Yes. Money. It's Otsy 10/21/14 10:34:17 AM
#27245   FAST TRACK is inevitable... They have already tied hispeed 10/21/14 10:26:35 AM
#27244   Is NITE Manipulating this Stock to artificially keep Setay 10/21/14 10:10:28 AM
#27243   Fast Track Designation: "Fast Track designation is intended joe_techi 10/21/14 09:13:20 AM
#27242   Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes bulldurham 10/21/14 09:07:19 AM
#27241   THIS IS HOW LONG YOU SHOULD EXPECT TO Emmmci 10/21/14 09:00:03 AM
#27240   Unless they are fast tracked which is the pjbwheeeze 10/21/14 08:58:12 AM
#27239   I would say this statement from Waggoner in bulldurham 10/21/14 08:31:56 AM
#27238   These are troubling times as never before seen Heimie1 10/20/14 11:12:40 PM
#27237   It's Time to Revisit Nuvilex, Inc. and its PetePham 10/20/14 10:18:18 PM
#27236   THIS IS HOW LONG YOU SHOULD EXPECT TO LuCo 10/20/14 10:02:16 PM
#27234   Unless Nuvilex says the studies have begun I LuCo 10/20/14 06:47:13 PM
#27233   Nuvilex will most like get the same treatment Heimie1 10/20/14 06:01:38 PM
#27232   Well said Setay.. Mariam* 10/20/14 04:10:02 PM
#27231   Nuvilex Contracts With University of Veterinary Medicine in bulldurham 10/20/14 03:27:46 PM
#27230   Bull- you should never use the word Traderintx 10/20/14 02:24:21 PM
#27229   Great news...Nuvilex will hit to $1 pretty soon. PetePham 10/20/14 12:17:29 PM
#27227   You are not wrong BUT Market Makers use foxmeadows1 10/20/14 11:53:54 AM
#27226   If All Goes Well...or even Most or Some...The Setay 10/20/14 11:43:07 AM
#27225   This isn't going to be an overnight success. Heimie1 10/20/14 11:29:59 AM
#27224   Just add 435 more shares to my holdings! hispstock 10/20/14 11:19:14 AM
#27223   I have been saying that...given that Dr. Günzburg bulldurham 10/20/14 10:26:44 AM
#27222   Time to get in FOLKS. 3/4 OF hispeed 10/20/14 10:20:30 AM
#27221   Good DD. I believe you are correct! Heimie1 10/20/14 10:12:44 AM
#27220   Good Morning Fellow Investors, avobill 10/20/14 10:09:48 AM
#27219   Could Nuvilex already know that the cells are rudygerner 10/20/14 09:58:53 AM
#27218   OTC doesn't trade premarket. I believe those trades Carson1 10/20/14 09:20:00 AM
#27217 NVLX up to $.245 with 12,500 shares Heimie1 10/20/14 09:17:47 AM